ACADIA Pharmaceuticals’s Outperform Rating Reaffirmed at Zacks (ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “outperform” rating reaffirmed by Zacks in a research note issued to investors on Wednesday, AmericanBankingNews.com reports. They currently have a $26.00 target price on the stock. Zacks‘ price target suggests a potential upside of 8.70% from the company’s current price.
Zacks‘ analyst wrote, “On Sunday, January 12, 2014, we arrived in San Francisco, CA for the annual JP Morgan Healthcare Conference, as well as the parallel Biotech showcase and OneMedForum Conferences. This was the eighth year in a row that we made the trip to San Francisco for these events, which are a must-attend for serious healthcare investors. During my three days in San Francisco, I conducted 25 one-on-one meetings with various managements of small and mid-cap biotechnology and specialty pharmaceutical companies. Below are some “notes” from our meeting with Acadia Pharmaceuticals.”
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded down 0.79% during mid-day trading on Wednesday, hitting $23.73. The stock had a trading volume of 431,750 shares. ACADIA Pharmaceuticals has a 1-year low of $5.60 and a 1-year high of $29.73. The stock’s 50-day moving average is $24.1 and its 200-day moving average is $22.55. The company’s market cap is $2.156 billion.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.